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CSPonclusions
lthough many challenges in the evolution of long-term DT
ith LVADs for advanced heart failure have been ad-
ressed, many hurdles remain.
It will be necessary for outcomes to improve beyond
EMATCH to transfer the sense of great potential held by
hose with pioneering spirit to those who are waiting for
vidence of substantial benefit to choose DT as a standard of
are from among the growing number of alternative thera-
ies. A field-wide goal of 50% 2-year survival seems rea-
onable at this stage.
In the future, DT will become less demanding as (1)
evices evolve,19,20 (2) management becomes standardized,
nd (3) patient selection improves first within current ad-
anced, REMATCH-like indications then followed by less-
dvanced heart failure as justified by outcomes. Until then,
issemination must be responsibly done among centers will-
ng to approach this with the necessary commitment, re-
ources, and patience.
It is not unreasonable to expect that DT may eventually
each outcomes on par with heart transplantation, especially
hen 10% to 15% mortality on the waiting list is added to
urrent posttransplant survival curves. It is worth remem-
ering that when heart transplantation was started, out-
omes were not too different than the early pioneering
xperiences with DT and that approximately 2 decades were
equired to evolve transplantation into the standard of care
f today.1,21
This experience of improving outcomes with DT should
ncourage continued pioneering with ventricular assist de-
ices for the treatment of advanced heart failure. For many
atients at or nearing end-stage heart failure, there is no
ther alternative at the present time that is equally
romising.
The authors acknowledge the valuable contributions made by
erry Heatley with data analysis. We thank Thoratec for providing
tatistical resources and access to updated REMATCH trial data.
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iscussion
r Cleveland (Denver, Colo). Jim, I congratulate you and your
oauthors at the Utah artificial heart program for achieving exem-
lary outcomes with a complex and challenging group of patients
ndergoing LVAD therapy as sole therapy for advanced heart
ailure. Again, Jim did a good job emphasizing and placing this
roup of patients and the results of the study in the context of the
act that these are critically ill patients. All had class IV congestive
eart failure for at least 90 days. All had an ejection fraction less
han 25%. All had a VO2 max less than 12 mL/kg/min, and most
mportant all had no other therapy (ie, heart transplantation). The
rinciple finding of the present study in this cohort of 23 patients
ndergoing DT in Utah is a 1-year survival of 77% versus 52% in
he surgically implanted destination group in the REMATCH trial.
articularly noteworthy is the subsequent 2-year survival of 77%
n Dr Long’s cohort versus only 30% in the REMATCH cohort.
If one considers the nature of this therapy for heart failure, therere 3 main mechanisms that could be offered to explain the
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Long et al Cardiopulmonary Support and Physiologymproved outcomes seen in your study. First is earlier patient
mplant. Obviously these are sick but not moribund patients, and
ou alluded to that, perhaps if their sodium was a little higher,
erhaps if their blood pressure was a little higher. Second is
mprovement in the HeartMate or LVAD technology itself. Third
s improvement in patient management. Which of these 3 to do you
elieve is most operant in providing for these results?
Dr Long. In this era I think patient management is the most
ritical step by which we can improve this field. Certainly as
evices improve we are going to see added reliability and dura-
ility, but we have not yet been able to identify that in the limited
umbers we’ve seen. Reduction in mortality because of device
ailure is largely the result of managing patients better through the
erioperative period. We think the reduction in infection, the first
eading cause of mortality in the REMATCH trial, is also largely
he result of infection, but clearly as devices improve, get smaller
ith percutaneous leads that are smaller, it will be much easier to
educe infections, much easier to implant these, and have a more
urable device, moving beyond 2-year devices into the 4 range.
atient selection is critical. Now we are constrained to the
EMATCH-like patients largely because of Centers for Medicare
nd Medicaid Services constraints and the regulatory approval
rocess. I think if we are going to do this effectively we have to
ove beyond that, but we really can’t move beyond that until we t
The Journal of Thoracicet some good results with those kinds of patients. I think it is
mportant for centers across this country to set targets of 50%
-year survivorship, and if we do achieve that across this field I
hink we earn the right to move to a less ill patient population
nalogous to those who were in the REMATCH trial.
Dr Cleveland. Second, as discussed in your article, and it’s
eally a well-written and clear article, DT has been offered only to
small number of patients. I think a reason for this is cost. Eric
ose and colleagues published subsequent cost data from the
EMATCH trial suggesting that with DT if the patient incurs
omplications perioperatively, particularly that of sepsis or bleed-
ng, the cost of this therapy increases to near-prohibitive levels. Do
ou have associated data? I know you didn’t present here today,
ut do you have data suggesting that with your improved outcomes
he cost of the therapy is less and therefore it may make this more
pproachable by many centers?
Dr Long. Your observation is right on. The destination field
eally didn’t begin picking up post-REMATCH until Centers for
edicare and Medicaid Services approval was in place, so that
ives you some indication how important reimbursement is to this.
n more recent studies yet to be released, we’re finding that we can
ecrease this to the $140,000 range and to the $130,000 range in
hose without complications.
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